Educational Symposium
Updates on Therapeutic Options for Anemia in Kidney Diseases
November 03, 2022 | 12:45 PM - 01:45 PM
Location: Regency Ballroom T, Hyatt Regency Orlando
Session Description
Anemia is an important and frequent complication of CKD that is often poorly diagnosed and undertreated in patients with early-stage CKD. When left untreated or undertreated, anemia due to CKD is associated with poor clinical outcomes and leads to a substantial burden on patients and healthcare systems.
This symposium provides an update on anemia treatment options for patients with non–dialysis-dependent CKD. The symposium also provides insights on the safety and efficacy of hypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs).
Support is provided by an educational grant from GlaxoSmithKline.
Learning Objective(s)
- Discuss management options to treat anemia in nondialysis CKD
- Analyze the cardiovascular complications of treating anemia
- Compare the efficacy of HIF-PHIs with erythropoiesis-stimulating agents
Learning Pathway(s)
- CKD Non-Dialysis
Moderator
- Fredric O. Finkelstein, MD
Presentations
- Introduction
12:45 PM - 12:55 PM
Fredric O. Finkelstein, MD
- Management of Anemia in Nondialysis CKD: Current Recommendations
12:55 PM - 01:15 PM
Bruce M. Robinson, MD, MS, FASN
- Efficacy and Cardiovascular Safety of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors
01:15 PM - 01:35 PM
Nupur Gupta, MD
- Questions and Answers
01:35 PM - 01:45 PM